| 1. Trejo A, Arzeno H, Browner M, Chanda S, Cheng S, Comer DD, Dalrymple SA, Dunten P, Lafargue J, Lovejoy B, Freire-Moar J, Lim J, Mcintosh J, Miller J, Papp E, Reuter D, Roberts R, Sanpablo F, Saunders J, Song K, Villasenor A, Warren SD, Welch M, Weller P, Whiteley PE, Zeng L, Goldstein DM.. (2003) Design and synthesis of 4-azaindoles as inhibitors of p38 MAP kinase.. J Med Chem, 46 (22): (4702-4713). [PMID:14561090] [10.1021/jm0301787] |
| 2. Rushe M, Silvian L, Bixler S, Chen LL, Cheung A, Bowes S, Cuervo H, Berkowitz S, Zheng T, Guckian K et al.. (2008) Structure of a NEMO/IKK-associating domain reveals architecture of the interaction site.. Structure, 16 (5): (798-808). [PMID:18462684] [10.1021/op500134e] |
| 3. Adrián FJ, Ding Q, Sim T, Velentza A, Sloan C, Liu Y, Zhang G, Hur W, Ding S, Manley P et al.. (2006) Allosteric inhibitors of Bcr-abl-dependent cell proliferation.. Nat Chem Biol, 2 (2): (95-102). [PMID:16415863] [10.1021/op500134e] |
| 4. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C et al.. (2007) Patterns of somatic mutation in human cancer genomes.. Nature, 446 (7132): (153-8). [PMID:17344846] [10.1021/op500134e] |
| 5. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Castaneda S, Cornelius LA, Das J, Doweyko AM et al.. (2004) Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.. J Med Chem, 47 (27): (6658-61). [PMID:15615512] [10.1021/op500134e] |
| 6. Podolin PL, Callahan JF, Bolognese BJ, Li YH, Carlson K, Davis TG, Mellor GW, Evans C, Roshak AK. (2005) Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IkappaB Kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell Proliferation.. J Pharmacol Exp Ther, 312 (1): (373-81). [PMID:15316093] [10.1021/op500134e] |
| 7. Szczepankiewicz BG, Kosogof C, Nelson LT, Liu G, Liu B, Zhao H, Serby MD, Xin Z, Liu M, Gum RJ et al.. (2006) Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity.. J Med Chem, 49 (12): (3563-80). [PMID:16759099] [10.1021/op500134e] |
| 8. Oyarzabal J, Zarich N, Albarran MI, Palacios I, Urbano-Cuadrado M, Mateos G, Reymundo I, Rabal O, Salgado A, Corrionero A et al.. (2010) Discovery of mitogen-activated protein kinase-interacting kinase 1 inhibitors by a comprehensive fragment-oriented virtual screening approach.. J Med Chem, 53 (18): (6618-28). [PMID:20722422] [10.1021/op500134e] |
| 9. Devadas B, Selness SR, Xing L, Madsen HM, Marrufo LD, Shieh H, Messing DM, Yang JZ, Morgan HM, Anderson GD et al.. (2011) Substituted N-aryl-6-pyrimidinones: a new class of potent, selective, and orally active p38 MAP kinase inhibitors.. Bioorg Med Chem Lett, 21 (13): (3856-60). [PMID:21620699] [10.1021/op500134e] |
| 10. Aston NM, Bamborough P, Buckton JB, Edwards CD, Holmes DS, Jones KL, Patel VK, Smee PA, Somers DO, Vitulli G et al.. (2009) p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression.. J Med Chem, 52 (20): (6257-69). [PMID:19772287] [10.1021/op500134e] |
| 11. Fancelli D, Moll J, Varasi M, Bravo R, Artico R, Berta D, Bindi S, Cameron A, Candiani I, Cappella P et al.. (2006) 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile.. J Med Chem, 49 (24): (7247-51). [PMID:17125279] [10.1021/op500134e] |
| 12. Apsel B, Blair JA, Gonzalez B, Nazif TM, Feldman ME, Aizenstein B, Hoffman R, Williams RL, Shokat KM, Knight ZA. (2008) Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.. Nat Chem Biol, 4 (11): (691-9). [PMID:18849971] [10.1021/op500134e] |
| 13. Doe C, Bentley R, Behm DJ, Lafferty R, Stavenger R, Jung D, Bamford M, Panchal T, Grygielko E, Wright LL et al.. (2007) Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities.. J Pharmacol Exp Ther, 320 (1): (89-98). [PMID:17018693] [10.1021/op500134e] |
| 14. Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B, Karaman MW, Pratz KW, Pallares G, Chao Q et al.. (2009) AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).. Blood, 114 (14): (2984-92). [PMID:19654408] [10.1021/op500134e] |
| 15. Wen D, Nong Y, Morgan JG, Gangurde P, Bielecki A, Dasilva J, Keaveney M, Cheng H, Fraser C, Schopf L et al.. (2006) A selective small molecule IkappaB Kinase beta inhibitor blocks nuclear factor kappaB-mediated inflammatory responses in human fibroblast-like synoviocytes, chondrocytes, and mast cells.. J Pharmacol Exp Ther, 317 (3): (989-1001). [PMID:16525037] [10.1021/op500134e] |
| 16. Burke JR, Pattoli MA, Gregor KR, Brassil PJ, MacMaster JF, McIntyre KW, Yang X, Iotzova VS, Clarke W, Strnad J et al.. (2003) BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice.. J Biol Chem, 278 (3): (1450-6). [PMID:12403772] [10.1021/op500134e] |
| 17. Goodfellow VS, Loweth CJ, Ravula SB, Wiemann T, Nguyen T, Xu Y, Todd DE, Sheppard D, Pollack S, Polesskaya O et al.. (2013) Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.. J Med Chem, 56 (20): (8032-48). [PMID:24044867] [10.1021/op500134e] |
| 18. Lee SL, Hsu EC, Chou CC, Chuang HC, Bai LY, Kulp SK, Chen CS. (2011) Identification and characterization of a novel integrin-linked kinase inhibitor.. J Med Chem, 54 (18): (6364-74). [PMID:21823616] [10.1021/op500134e] |
| 19. Lafleur K, Huang D, Zhou T, Caflisch A, Nevado C. (2009) Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4).. J Med Chem, 52 (20): (6433-46). [PMID:19788238] [10.1021/op500134e] |
| 20. Anderson DR, Meyers MJ, Vernier WF, Mahoney MW, Kurumbail RG, Caspers N, Poda GI, Schindler JF, Reitz DB, Mourey RJ. (2007) Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2).. J Med Chem, 50 (11): (2647-54). [PMID:17480064] [10.1021/op500134e] |
| 21. Okuzumi T, Fiedler D, Zhang C, Gray DC, Aizenstein B, Hoffman R, Shokat KM. (2009) Inhibitor hijacking of Akt activation.. Nat Chem Biol, 5 (7): (484-93). [PMID:19465931] [10.1021/op500134e] |
| 22. Papeo G, Posteri H, Borghi D, Busel AA, Caprera F, Casale E, Ciomei M, Cirla A, Corti E, D'Anello M et al.. (2015) Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy.. J Med Chem, 58 (17): (6875-98). [PMID:26222319] [10.1021/op500134e] |
| 23. Uckun FM, Dibirdik I, Qazi S, Vassilev A, Ma H, Mao C, Benyumov A, Emami KH. (2007) Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK).. Bioorg Med Chem, 15 (2): (800-14). [PMID:17098432] [10.1021/op500134e] |
| 24. Miwatashi S, Arikawa Y, Kotani E, Miyamoto M, Naruo K, Kimura H, Tanaka T, Asahi S, Ohkawa S. (2005) Novel inhibitor of p38 MAP kinase as an anti-TNF-alpha drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent.. J Med Chem, 48 (19): (5966-79). [PMID:16162000] [10.1021/op500134e] |
| 25. Aronov AM, Tang Q, Martinez-Botella G, Bemis GW, Cao J, Chen G, Ewing NP, Ford PJ, Germann UA, Green J et al.. (2009) Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control.. J Med Chem, 52 (20): (6362-8). [PMID:19827834] [10.1021/op500134e] |
| 26. Mbalaviele G, Sommers CD, Bonar SL, Mathialagan S, Schindler JF, Guzova JA, Shaffer AF, Melton MA, Christine LJ, Tripp CS et al.. (2009) A novel, highly selective, tight binding IkappaB kinase-2 (IKK-2) inhibitor: a tool to correlate IKK-2 activity to the fate and functions of the components of the nuclear factor-kappaB pathway in arthritis-relevant cells and animal models.. J Pharmacol Exp Ther, 329 (1): (14-25). [PMID:19168710] [10.1021/op500134e] |
| 27. Cui J, Zhu L, Xia X, Wang HY, Legras X, Hong J, Ji J, Shen P, Zheng S, Chen ZJ et al.. (2010) NLRC5 negatively regulates the NF-kappaB and type I interferon signaling pathways.. Cell, 141 (3): (483-96). [PMID:20434986] [10.1021/op500134e] |
| 28. Anthony NG, Baiget J, Berretta G, Boyd M, Breen D, Edwards J, Gamble C, Gray AI, Harvey AL, Hatziieremia S et al.. (2017) Inhibitory Kappa B Kinase α (IKKα) Inhibitors That Recapitulate Their Selectivity in Cells against Isoform-Related Biomarkers.. J Med Chem, 60 (16): (7043-7066). [PMID:28737909] [10.1021/op500134e] |
| 29. Tan L, Gurbani D, Weisberg EL, Jones DS, Rao S, Singer WD, Bernard FM, Mowafy S, Jenney A, Du G et al.. (2017) Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors.. Bioorg Med Chem, 25 (4): (1320-1328). [PMID:28038940] [10.1021/op500134e] |
| 30. Pippione AC, Sainas S, Federico A, Lupino E, Piccinini M, Kubbutat M, Contreras JM, Morice C, Barge A, Ducime A et al.. (2018) N-Acetyl-3-aminopyrazoles block the non-canonical NF-kB cascade by selectively inhibiting NIK.. Medchemcomm, 9 (6): (963-968). [PMID:30108985] [10.1039/C8MD00068A] |
| 31. Patel S, Harris SF, Gibbons P, Deshmukh G, Gustafson A, Kellar T, Lin H, Liu X, Liu Y, Liu Y et al.. (2015) Scaffold-Hopping and Structure-Based Discovery of Potent, Selective, And Brain Penetrant N-(1H-Pyrazol-3-yl)pyridin-2-amine Inhibitors of Dual Leucine Zipper Kinase (DLK, MAP3K12).. J Med Chem, 58 (20): (8182-99). [PMID:26431428] [10.1021/op500134e] |
| 32. Das J, Furch JA, Liu C, Moquin RV, Lin J, Spergel SH, McIntyre KW, Shuster DJ, O'Day KD, Penhallow B et al.. (2006) Discovery and SAR of 2-amino-5-(thioaryl)thiazoles as potent and selective Itk inhibitors.. Bioorg Med Chem Lett, 16 (14): (3706-12). [PMID:16682193] [10.1021/op500134e] |
| 33. Zhang H, Xu L, Qin X, Chen X, Cong H, Hu L, Chen L, Miao Z, Zhang W, Cai Z et al.. (2019) N-(7-Cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetamido)phenoxy)benzo[d]thiazol-2-yl)cyclopropanecarboxamide (TAK-632) Analogues as Novel Necroptosis Inhibitors by Targeting Receptor-Interacting Protein Kinase 3 (RIPK3): Synthesis, Structure-Activity Relationships, and in Vivo Efficacy.. J Med Chem, 62 (14): (6665-6681). [PMID:31095385] [10.1021/op500134e] |
| 34. Pomel V, Klicic J, Covini D, Church DD, Shaw JP, Roulin K, Burgat-Charvillon F, Valognes D, Camps M, Chabert C et al.. (2006) Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.. J Med Chem, 49 (13): (3857-71). [PMID:16789742] [10.1021/op500134e] |
| 35. Ding Y, Xue Q, Liu S, Hu K, Wang D, Wang T, Li Y, Guo H, Hao X, Ge W et al.. (2020) Identification of Parthenolide Dimers as Activators of Pyruvate Kinase M2 in Xenografts of Glioblastoma Multiforme in Vivo.. J Med Chem, 63 (4): (1597-1611). [PMID:31977207] [10.1021/op500134e] |
| 36. Czako B, Marszalek JR, Burke JP, Mandal P, Leonard PG, Cross JB, Mseeh F, Jiang Y, Chang EQ, Suzuki E et al.. (2020) Discovery of IACS-9439, a Potent, Exquisitely Selective, and Orally Bioavailable Inhibitor of CSF1R.. J Med Chem, 71 (13): (1755-70). [PMID:32787110] [10.1021/acs.jmedchem.0c00936] |
| 37. Erki Enkvist, Darja Lavogina, Gerda Raidaru, Angela Vaasa, Indrek Viil, Marje Lust, Kaido Viht, Asko Uri,. (2006-11-28) Conjugation of adenosine and hexa-(D-arginine) leads to a nanomolar bisubstrate-analog inhibitor of basophilic protein kinases.. Journal of medicinal chemistry, 49 ((24)): ( 7150-7159 ). [PMID:17125267] |
| 38. Sharon Gauci,Andreas O Helbig,Monique Slijper,Jeroen Krijgsveld,Albert J R Heck,Shabaz Mohammed. (2009-05-06) Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.. Analytical chemistry, 81 ((11)): (4493-4501). [PMID:19413330] |
| 39. Pevarello P, Brasca MG, Amici R, Orsini P, Traquandi G, Corti L, Piutti C, Sansonna P, Villa M, Pierce BS, Pulici M, Giordano P, Martina K, Fritzen EL, Nugent RA, Casale E, Cameron A, Ciomei M, Roletto F, Isacchi A, Fogliatto G, Pesenti E, Pastori W, Marsiglio A, Leach KL, Clare PM, Fiorentini F, Varasi M, Vulpetti A, Warpehoski MA.. (2004) 3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding.. J Med Chem, 47 (13): (3367-3380). [PMID:15189033] [10.1021/jm031145u] |
| 40. Bonafoux D, Bonar S, Christine L, Clare M, Donnelly A, Guzova J, Kishore N, Lennon P, Libby A, Mathialagan S, McGhee W, Rouw S, Sommers C, Tollefson M, Tripp C, Weier R, Wolfson S, Min Y.. (2005) Inhibition of IKK-2 by 2-[(aminocarbonyl)amino]-5-acetylenyl-3-thiophenecarboxamides.. Bioorg Med Chem Lett, 15 (11): (2870-2875). [PMID:15911271] [10.1016/j.bmcl.2005.03.090] |
| 41. Zhao H, Serby MD, Xin Z, Szczepankiewicz BG, Liu M, Kosogof C, Liu B, Nelson LT, Johnson EF, Wang S, Pederson T, Gum RJ, Clampit JE, Haasch DL, Abad-Zapatero C, Fry EH, Rondinone C, Trevillyan JM, Sham HL, Liu G.. (2006) Discovery of potent, highly selective, and orally bioavailable pyridine carboxamide c-Jun NH2-terminal kinase inhibitors.. J Med Chem, 49 (15): (4455-4458). [PMID:16854050] [10.1021/jm060465l] |
| 42. Borzilleri RM, Bhide RS, Barrish JC, D'Arienzo CJ, Derbin GM, Fargnoli J, Hunt JT, Jeyaseelan R, Kamath A, Kukral DW, Marathe P, Mortillo S, Qian L, Tokarski JS, Wautlet BS, Zheng X, Lombardo LJ.. (2006) Discovery and evaluation of N-cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5- ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2.. J Med Chem, 49 (13): (3766-3769). [PMID:16789733] [10.1021/jm060347y] |
| 43. Leftheris K, Ahmed G, Chan R, Dyckman AJ, Hussain Z, Ho K, Hynes J, Letourneau J, Li W, Lin S, Metzger A, Moriarty KJ, Riviello C, Shimshock Y, Wen J, Wityak J, Wrobleski ST, Wu H, Wu J, Desai M, Gillooly KM, Lin TH, Loo D, McIntyre KW, Pitt S, Shen DR, Shuster DJ, Zhang R, Diller D, Doweyko A, Sack J, Baldwin J, Barrish J, Dodd J, Henderson I, Kanner S, Schieven GL, Webb M.. (2004) The discovery of orally active triaminotriazine aniline amides as inhibitors of p38 MAP kinase.. J Med Chem, 47 (25): (6283-6291). [PMID:15566298] [10.1021/jm049521d] |
| 44. Shrestha S, Bhattarai BR, Cho H, Choi JK, Cho H.. (2007) PTP1B inhibitor Ertiprotafib is also a potent inhibitor of IkappaB kinase beta (IKK-beta).. Bioorg Med Chem Lett, 17 (10): (2728-2730). [PMID:17407812] [10.1016/j.bmcl.2007.03.001] |
| 45. Slack-Davis JK, Martin KH, Tilghman RW, Iwanicki M, Ung EJ, Autry C, Luzzio MJ, Cooper B, Kath JC, Roberts WG, Parsons JT.. (2007) Cellular characterization of a novel focal adhesion kinase inhibitor.. J Biol Chem, 282 (20): (14845-14852). [PMID:17395594] [10.1074/jbc.m606695200] |
| 46. Feng Y, Yin Y, Weiser A, Griffin E, Cameron MD, Lin L, Ruiz C, Schürer SC, Inoue T, Rao PV, Schröter T, Lograsso P.. (2008) Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors.. J Med Chem, 51 (21): (6642-6645). [PMID:18834107] [10.1021/jm800986w] |
| 47. Xia Z, Knaak C, Ma J, Beharry ZM, McInnes C, Wang W, Kraft AS, Smith CD.. (2009) Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases.. J Med Chem, 52 (1): (74-86). [PMID:19072652] [10.1021/jm800937p] |
| 48. Lorenzo P, Alvarez R, Ortiz MA, Alvarez S, Piedrafita FJ, de Lera AR.. (2008) Inhibition of IkappaB kinase-beta and anticancer activities of novel chalcone adamantyl arotinoids.. J Med Chem, 51 (17): (5431-5440). [PMID:18702457] [10.1021/jm800285f] |
| 49. Nagarajan S, Doddareddy Mr, Choo H, Cho YS, Oh KS, Lee BH, Pae AN.. (2009) IKKbeta inhibitors identification part I: homology model assisted structure based virtual screening.. Bioorg Med Chem, 17 (7): (2759-2766). [PMID:19285872] [10.1016/j.bmc.2009.02.041] |
| 50. Lin JC, Yang SC, Hong TM, Yu SL, Shi Q, Wei L, Chen HY, Yang PC, Lee KH.. (2009) Phenanthrene-based tylophorine-1 (PBT-1) inhibits lung cancer cell growth through the Akt and NF-kappaB pathways.. J Med Chem, 52 (7): (1903-1911). [PMID:19284764] [10.1021/jm801344j] |
| 51. Li J, Kaoud TS, Laroche C, Dalby KN, Kerwin SM.. (2009) Synthesis and biological evaluation of p38alpha kinase-targeting dialkynylimidazoles.. Bioorg Med Chem Lett, 19 (22): (6293-6297). [PMID:19822424] [10.1016/j.bmcl.2009.09.094] |
| 52. Wee XK, Yeo WK, Zhang B, Tan VB, Lim KM, Tay TE, Go ML.. (2009) Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.. Bioorg Med Chem, 17 (21): (7562-7571). [PMID:19783149] [10.1016/j.bmc.2009.09.008] |
| 53. Bhattarai BR, Ko JH, Shrestha S, Kafle B, Cho H, Kang JH, Cho H.. (2010) Inhibition of IKK-beta: a new development in the mechanism of the anti-obesity effects of PTP1B inhibitors SA18 and SA32.. Bioorg Med Chem Lett, 20 (3): (1075-1077). [PMID:20044255] [10.1016/j.bmcl.2009.12.033] |
| 54. Qiao L, Choi S, Case A, Gainer TG, Seyb K, Glicksman MA, Lo DC, Stein RL, Cuny GD.. (2009) Structure-activity relationship study of EphB3 receptor tyrosine kinase inhibitors.. Bioorg Med Chem Lett, 19 (21): (6122-6126). [PMID:19783434] [10.1016/j.bmcl.2009.09.010] |
| 55. Yu H, Jung Y, Kim H, Lee J, Oh CH, Yoo KH, Sim T, Hah JM.. (2010) 1,4-dihydropyrazolo[4,3-d]imidazole phenyl derivatives: a novel type II Raf kinase inhibitors.. Bioorg Med Chem Lett, 20 (12): (3805-3808). [PMID:20466542] [10.1016/j.bmcl.2010.04.039] |
| 56. Deng X, Lim SM, Zhang J, Gray NS.. (2010) Broad spectrum alkynyl inhibitors of T315I Bcr-Abl.. Bioorg Med Chem Lett, 20 (14): (4196-4200). [PMID:20541934] [10.1016/j.bmcl.2010.05.043] |
| 57. Peddibhotla S, Shi R, Khan P, Smith LH, Mangravita-Novo A, Vicchiarelli M, Su Y, Okolotowicz KJ, Cashman JR, Reed JC, Roth GP.. (2010) Inhibition of protein kinase C-driven nuclear factor-kappaB activation: synthesis, structure-activity relationship, and pharmacological profiling of pathway specific benzimidazole probe molecules.. J Med Chem, 53 (12): (4793-4797). [PMID:20481485] [10.1021/jm1000248] |
| 58. Ye P, Kuhn C, Juan M, Sharma R, Connolly B, Alton G, Liu H, Stanton R, Kablaoui NM.. (2011) Potent and selective thiophene urea-templated inhibitors of S6K.. Bioorg Med Chem Lett, 21 (2): (849-852). [PMID:21185721] [10.1016/j.bmcl.2010.11.069] |
| 59. Probst GD, Bowers S, Sealy JM, Truong AP, Hom RK, Galemmo RA, Konradi AW, Sham HL, Quincy DA, Pan H, Yao N, Lin M, Tóth G, Artis DR, Zmolek W, Wong K, Qin A, Lorentzen C, Nakamura DF, Quinn KP, Sauer JM, Powell K, Ruslim L, Wright S, Chereau D, Ren Z, Anderson JP, Bard F, Yednock TA, Griswold-Prenner I.. (2011) Highly selective c-Jun N-terminal kinase (JNK) 2 and 3 inhibitors with in vitro CNS-like pharmacokinetic properties prevent neurodegeneration.. Bioorg Med Chem Lett, 21 (1): (315-319). [PMID:21112785] [10.1016/j.bmcl.2010.11.010] |
| 60. Qiu X, Du Y, Lou B, Zuo Y, Shao W, Huo Y, Huang J, Yu Y, Zhou B, Du J, Fu H, Bu X.. (2010) Synthesis and identification of new 4-arylidene curcumin analogues as potential anticancer agents targeting nuclear factor-κB signaling pathway.. J Med Chem, 53 (23): (8260-8273). [PMID:21070043] [10.1021/jm1004545] |
| 61. Shimizu H, Yamasaki T, Yoneda Y, Muro F, Hamada T, Yasukochi T, Tanaka S, Toki T, Yokoyama M, Morishita K, Iimura S.. (2011) Discovery of imidazo[1,2-b]pyridazines as IKKβ inhibitors. Part 3: exploration of effective compounds in arthritis models.. Bioorg Med Chem Lett, 21 (15): (4550-4555). [PMID:21705219] [10.1016/j.bmcl.2011.05.115] |
| 62. Lumeras W, Vidal L, Vidal B, Balagué C, Orellana A, Maldonado M, Domínguez M, Segarra V, Caturla F.. (2011) 1,7-Naphthyridine 1-oxides as novel potent and selective inhibitors of p38 mitogen activated protein kinase.. J Med Chem, 54 (22): (7899-7910). [PMID:21999461] [10.1021/jm200975u] |
| 63. Ishikawa T, Seto M, Banno H, Kawakita Y, Oorui M, Taniguchi T, Ohta Y, Tamura T, Nakayama A, Miki H, Kamiguchi H, Tanaka T, Habuka N, Sogabe S, Yano J, Aertgeerts K, Kamiyama K.. (2011) Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold.. J Med Chem, 54 (23): (8030-8050). [PMID:22003817] [10.1021/jm2008634] |
| 64. Powell NA, Kohrt JT, Filipski KJ, Kaufman M, Sheehan D, Edmunds JE, Delaney A, Wang Y, Bourbonais F, Lee DY, Schwende F, Sun F, McConnell P, Catana C, Chen H, Ohren J, Perrin LA.. (2012) Novel and selective spiroindoline-based inhibitors of Sky kinase.. Bioorg Med Chem Lett, 22 (1): (190-193). [PMID:22119469] [10.1016/j.bmcl.2011.11.036] |
| 65. Caruso M, Valsasina B, Ballinari D, Bertrand J, Brasca MG, Caldarelli M, Cappella P, Fiorentini F, Gianellini LM, Scolaro A, Beria I.. (2012) 5-(2-amino-pyrimidin-4-yl)-1H-pyrrole and 2-(2-amino-pyrimidin-4-yl)-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-one derivatives as new classes of selective and orally available Polo-like kinase 1 inhibitors.. Bioorg Med Chem Lett, 22 (1): (96-101). [PMID:22154349] [10.1016/j.bmcl.2011.11.065] |
| 66. Cuny GD, Ulyanova NP, Patnaik D, Liu JF, Lin X, Auerbach K, Ray SS, Xian J, Glicksman MA, Stein RL, Higgins JM.. (2012) Structure-activity relationship study of beta-carboline derivatives as haspin kinase inhibitors.. Bioorg Med Chem Lett, 22 (5): (2015-2019). [PMID:22335895] [10.1016/j.bmcl.2012.01.028] |
| 67. Zhang J, Deng X, Choi HG, Alessi DR, Gray NS.. (2012) Characterization of TAE684 as a potent LRRK2 kinase inhibitor.. Bioorg Med Chem Lett, 22 (5): (1864-1869). [PMID:22335897] [10.1016/j.bmcl.2012.01.084] |
| 68. Song H, Lee YS, Roh EJ, Seo JH, Oh KS, Lee BH, Han H, Shin KJ.. (2012) Discovery of potent and selective rhodanine type IKKβ inhibitors by hit-to-lead strategy.. Bioorg Med Chem Lett, 22 (17): (5668-5674). [PMID:22858099] [10.1016/j.bmcl.2012.06.088] |
| 69. Baumgartner L, Sosa S, Atanasov AG, Bodensieck A, Fakhrudin N, Bauer J, Favero GD, Ponti C, Heiss EH, Schwaiger S, Ladurner A, Widowitz U, Loggia RD, Rollinger JM, Werz O, Bauer R, Dirsch VM, Tubaro A, Stuppner H.. (2011) Lignan derivatives from Krameria lappacea roots inhibit acute inflammation in vivo and pro-inflammatory mediators in vitro.. J Nat Prod, 74 (8): (1779-1786). [PMID:21800856] [10.1021/np200343t] |
| 70. Illig CR, Manthey CL, Wall MJ, Meegalla SK, Chen J, Wilson KJ, Ballentine SK, Desjarlais RL, Schubert C, Crysler CS, Chen Y, Molloy CJ, Chaikin MA, Donatelli RR, Yurkow E, Zhou Z, Player MR, Tomczuk BE.. (2011) Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).. J Med Chem, 54 (22): (7860-7883). [PMID:22039836] [10.1021/jm200900q] |
| 71. Reith AD, Bamborough P, Jandu K, Andreotti D, Mensah L, Dossang P, Choi HG, Deng X, Zhang J, Alessi DR, Gray NS.. (2012) GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor.. Bioorg Med Chem Lett, 22 (17): (5625-5629). [PMID:22863203] [10.1016/j.bmcl.2012.06.104] |
| 72. Gong L, Tan YC, Boice G, Abbot S, McCaleb K, Iyer P, Zuo F, Dal Porto J, Wong B, Jin S, Chang A, Tran P, Hsieh G, Niu L, Shao A, Reuter D, Lukacs CM, Ursula Kammlott R, Kuglstatter A, Goldstein D.. (2012) Discovery of a novel series of 4-quinolone JNK inhibitors.. Bioorg Med Chem Lett, 22 (24): (7381-7387). [PMID:23142618] [10.1016/j.bmcl.2012.10.066] |
| 73. Dolečková I, Cesnek M, Dračinský M, Brynda J, Voller J, Janeba Z, Kryštof V.. (2013) Synthesis and biological evaluation of guanidino analogues of roscovitine.. Eur J Med Chem, 62 (443-452). [PMID:23399722] [10.1016/j.ejmech.2013.01.021] |
| 74. Brown A, Shi Q, Moore TW, Yoon Y, Prussia A, Maddox C, Liotta DC, Shim H, Snyder JP.. (2013) Monocarbonyl curcumin analogues: heterocyclic pleiotropic kinase inhibitors that mediate anticancer properties.. J Med Chem, 56 (9): (3456-3466). [PMID:23550937] [10.1021/jm4002692] |
| 75. Mortensen DS, Sapienza J, Lee BG, Perrin-Ninkovic SM, Harris R, Shevlin G, Parnes JS, Whitefield B, Hickman M, Khambatta G, Bisonette RR, Peng S, Gamez JC, Leisten J, Narla RK, Fultz KE, Sankar S.. (2013) Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase.. Bioorg Med Chem Lett, 23 (6): (1588-1591). [PMID:23414803] [10.1016/j.bmcl.2013.01.110] |
| 76. Huang JJ, Wu XW, Jia JM, Guo XK, Xue X, Jiang ZY, Zhang SL, Zhang XJ, Sun HP, You QD.. (2013) Novel IKKβ inhibitors discovery based on the co-crystal structure by using binding-conformation-based and ligand-based method.. Eur J Med Chem, 63 (269-278). [PMID:23501112] [10.1016/j.ejmech.2013.01.045] |
| 77. Yu LF, Li YY, Su MB, Zhang M, Zhang W, Zhang LN, Pang T, Zhang RT, Liu B, Li JY, Li J, Nan FJ.. (2013) Development of Novel Alkene Oxindole Derivatives As Orally Efficacious AMP-Activated Protein Kinase Activators.. ACS Med Chem Lett, 4 (5): (475-480). [PMID:24900695] [10.1021/ml400028q] |
| 78. Lin WH, Hsu JT, Hsieh SY, Chen CT, Song JS, Yen SC, Hsu T, Lu CT, Chen CH, Chou LH, Yang YN, Chiu CH, Chen CP, Tseng YJ, Yen KJ, Yeh CF, Chao YS, Yeh TK, Jiaang WT.. (2013) Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).. Bioorg Med Chem, 21 (11): (2856-2867). [PMID:23618709] [10.1016/j.bmc.2013.03.083] |
| 79. Bowers S, Truong AP, Ye M, Aubele DL, Sealy JM, Neitz RJ, Hom RK, Chan W, Dappen MS, Galemmo RA, Konradi AW, Sham HL, Zhu YL, Beroza P, Tonn G, Zhang H, Hoffman J, Motter R, Fauss D, Tanaka P, Bova MP, Ren Z, Tam D, Ruslim L, Baker J, Pandya D, Diep L, Fitzgerald K, Artis DR, Anderson JP, Bergeron M.. (2013) Design and synthesis of highly selective, orally active Polo-like kinase-2 (Plk-2) inhibitors.. Bioorg Med Chem Lett, 23 (9): (2743-2749). [PMID:23522834] [10.1016/j.bmcl.2013.02.065] |
| 80. Akama T, Dong C, Virtucio C, Freund YR, Chen D, Orr MD, Jacobs RT, Zhang YK, Hernandez V, Liu Y, Wu A, Bu W, Liu L, Jarnagin K, Plattner JJ.. (2013) Discovery and structure-activity relationships of 6-(benzoylamino)benzoxaboroles as orally active anti-inflammatory agents.. Bioorg Med Chem Lett, 23 (21): (5870-5873). [PMID:24075731] [10.1016/j.bmcl.2013.08.096] |
| 81. García-Rodríguez J, Pérez-Rodríguez S, Ortiz MA, Pereira R, de Lera AR, Piedrafita FJ.. (2014) Inhibition of IκB kinase-β and IκB kinase-α by heterocyclic adamantyl arotinoids.. Bioorg Med Chem, 22 (4): (1285-1302). [PMID:24457093] [10.1016/j.bmc.2014.01.006] |
| 82. Suthar SK, Boon HL, Sharma M.. (2014) Novel lung adenocarcinoma and nuclear factor-kappa B (NF-κB) inhibitors: synthesis and evaluation of lantadene congeners.. Eur J Med Chem, 74 (135-144). [PMID:24457265] [10.1016/j.ejmech.2013.12.052] |
| 83. Shi Q, Tebben A, Dyckman AJ, Li H, Liu C, Lin J, Spergel S, Burke JR, McIntyre KW, Olini GC, Strnad J, Surti N, Muckelbauer JK, Chang C, An Y, Cheng L, Ruan Q, Leftheris K, Carter PH, Tino J, De Lucca GV.. (2014) Purine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseases.. Bioorg Med Chem Lett, 24 (9): (2206-2211). [PMID:24685542] [10.1016/j.bmcl.2014.02.075] |
| 84. Park CH, Lee C, Yang JS, Joe BY, Chun K, Kim H, Kim HY, Kang JS, Lee JI, Kim MH, Han G.. (2014) Discovery of thienopyrimidine-based FLT3 inhibitors from the structural modification of known IKKβ inhibitors.. Bioorg Med Chem Lett, 24 (12): (2655-2660). [PMID:24813730] [10.1016/j.bmcl.2014.04.058] |
| 85. Blake JF, Gaudino JJ, De Meese J, Mohr P, Chicarelli M, Tian H, Garrey R, Thomas A, Siedem CS, Welch MB, Kolakowski G, Kaus R, Burkard M, Martinson M, Chen H, Dean B, Dudley DA, Gould SE, Pacheco P, Shahidi-Latham S, Wang W, West K, Yin J, Moffat J, Schwarz JB.. (2014) Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2.. Bioorg Med Chem Lett, 24 (12): (2635-2639). [PMID:24813737] [10.1016/j.bmcl.2014.04.068] |
| 86. Menet CJ, Fletcher SR, Van Lommen G, Geney R, Blanc J, Smits K, Jouannigot N, Deprez P, van der Aar EM, Clement-Lacroix P, Lepescheux L, Galien R, Vayssiere B, Nelles L, Christophe T, Brys R, Uhring M, Ciesielski F, Van Rompaey L.. (2014) Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634.. J Med Chem, 57 (22): (9323-9342). [PMID:25369270] [10.1021/jm501262q] |
| 87. Hasumi K, Sato S, Saito T, Kato JY, Shirota K, Sato J, Suzuki H, Ohta S.. (2014) Design and synthesis of 5-[(2-chloro-6-fluorophenyl)acetylamino]-3-(4-fluorophenyl)-4-(4-pyrimidinyl)isoxazole (AKP-001), a novel inhibitor of p38 MAP kinase with reduced side effects based on the antedrug concept.. Bioorg Med Chem, 22 (15): (4162-4176). [PMID:24938496] [10.1016/j.bmc.2014.05.045] |
| 88. Li YX, Kang KH, Kim HJ, Kim SK.. (2014) In vitro induction of apoptosis by isosclerone from marine-derived fungus Aspergillus fumigatus.. Bioorg Med Chem Lett, 24 (16): (3923-3927). [PMID:25011914] [10.1016/j.bmcl.2014.06.042] |
| 89. Monika, Sharma A, Suthar SK, Aggarwal V, Lee HB, Sharma M.. (2014) Synthesis of lantadene analogs with marked in vitro inhibition of lung adenocarcinoma and TNF-α induced nuclear factor-kappa B (NF-κB) activation.. Bioorg Med Chem Lett, 24 (16): (3814-3818). [PMID:25027934] [10.1016/j.bmcl.2014.06.068] |
| 90. Jain SK, Singh S, Khajuria A, Guru SK, Joshi P, Meena S, Nadkarni JR, Singh A, Bharate SS, Bhushan S, Bharate SB, Vishwakarma RA.. (2014) Pyrano-isochromanones as IL-6 inhibitors: synthesis, in vitro and in vivo antiarthritic activity.. J Med Chem, 57 (16): (7085-7097). [PMID:25111439] [10.1021/jm500901e] |
| 91. Ye Q, Mao W, Zhou Y, Xu L, Li Q, Gao Y, Wang J, Li C, Xu Y, Xu Y, Liao H, Zhang L, Gao J, Li J, Pang T.. (2015) Synthesis and biological evaluation of 3-([1,2,4]triazolo[4,3-a]pyridin-3-yl)-4-(indol-3-yl)-maleimides as potent, selective GSK-3β inhibitors and neuroprotective agents.. Bioorg Med Chem, 23 (5): (1179-1188). [PMID:25662701] [10.1016/j.bmc.2014.12.026] |
| 92. Zhang CH, Zheng MW, Li YP, Lin XD, Huang M, Zhong L, Li GB, Zhang RJ, Lin WT, Jiao Y, Wu XA, Yang J, Xiang R, Chen LJ, Zhao YL, Cheng W, Wei YQ, Yang SY.. (2015) Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer.. J Med Chem, 58 (9): (3957-3974). [PMID:25835317] [10.1021/acs.jmedchem.5b00270] |
| 93. Yadav RR, Sharma S, Joshi P, Wani A, Vishwakarma RA, Kumar A, Bharate SB.. (2015) Meridianin derivatives as potent Dyrk1A inhibitors and neuroprotective agents.. Bioorg Med Chem Lett, 25 (15): (2948-2952). [PMID:26048785] [10.1016/j.bmcl.2015.05.034] |
| 94. Charnley AK, Convery MA, Lakdawala Shah A, Jones E, Hardwicke P, Bridges A, Ouellette M, Totoritis R, Schwartz B, King BW, Wisnoski DD, Kang J, Eidam PM, Votta BJ, Gough PJ, Marquis RW, Bertin J, Casillas L.. (2015) Crystal structures of human RIP2 kinase catalytic domain complexed with ATP-competitive inhibitors: Foundations for understanding inhibitor selectivity.. Bioorg Med Chem, 23 (21): (7000-7006). [PMID:26455654] [10.1016/j.bmc.2015.09.038] |
| 95. Sestito S, Nesi G, Daniele S, Martelli A, Digiacomo M, Borghini A, Pietra D, Calderone V, Lapucci A, Falasca M, Parrella P, Notarangelo A, Breschi MC, Macchia M, Martini C, Rapposelli S.. (2015) Design and synthesis of 2-oxindole based multi-targeted inhibitors of PDK1/Akt signaling pathway for the treatment of glioblastoma multiforme.. Eur J Med Chem, 105 (274-288). [PMID:26498573] [10.1016/j.ejmech.2015.10.020] |
| 96. Nakano H, Hasegawa T, Saito N, Furukawa K, Mukaida N, Kojima H, Okabe T, Nagano T.. (2015) Design and synthesis of an in vivo-efficacious PIM3 kinase inhibitor as a candidate anti-pancreatic cancer agent.. Bioorg Med Chem Lett, 25 (24): (5687-5693). [PMID:26547690] [10.1016/j.bmcl.2015.10.098] |
| 97. Simon-Szabó L, Kokas M, Greff Z, Boros S, Bánhegyi P, Zsákai L, Szántai-Kis C, Vantus T, Mandl J, Bánhegyi G, Vályi-Nagy I, Őrfi L, Ullrich A, Csala M, Kéri G.. (2016) Novel compounds reducing IRS-1 serine phosphorylation for treatment of diabetes.. Bioorg Med Chem Lett, 26 (2): (424-428). [PMID:26704265] [10.1016/j.bmcl.2015.11.099] |
| 98. Lee NY, Chung KS, Jin JS, Bang KS, Eom YJ, Hong CH, Nugroho A, Park HJ, An HJ.. (2015) Effect of Chicoric Acid on Mast Cell-Mediated Allergic Inflammation in Vitro and in Vivo.. J Nat Prod, 78 (12): (2956-2962). [PMID:26593037] [10.1021/acs.jnatprod.5b00668] |
| 99. Schiemann K, Mallinger A, Wienke D, Esdar C, Poeschke O, Busch M, Rohdich F, Eccles SA, Schneider R, Raynaud FI, Czodrowski P, Musil D, Schwarz D, Urbahns K, Blagg J.. (2016) Discovery of potent and selective CDK8 inhibitors from an HSP90 pharmacophore.. Bioorg Med Chem Lett, 26 (5): (1443-1451). [PMID:26852363] [10.1016/j.bmcl.2016.01.062] |
| 100. Daydé-Cazals B, Fauvel B, Singer M, Feneyrolles C, Bestgen B, Gassiot F, Spenlinhauer A, Warnault P, Van Hijfte N, Borjini N, Chevé G, Yasri A.. (2016) Rational Design, Synthesis, and Biological Evaluation of 7-Azaindole Derivatives as Potent Focused Multi-Targeted Kinase Inhibitors.. J Med Chem, 59 (8): (3886-3905). [PMID:27010810] [10.1021/acs.jmedchem.6b00087] |
| 101. Schroeder RL, Goyal N, Bratton M, Townley I, Pham NA, Tram P, Stone T, Geathers J, Nguyen K, Sridhar J.. (2016) Identification of quinones as novel PIM1 kinase inhibitors.. Bioorg Med Chem Lett, 26 (13): (3187-3191). [PMID:27173800] [10.1016/j.bmcl.2016.04.079] |
| 102. Rana S, Blowers EC, Tebbe C, Contreras JI, Radhakrishnan P, Kizhake S, Zhou T, Rajule RN, Arnst JL, Munkarah AR, Rattan R, Natarajan A.. (2016) Isatin Derived Spirocyclic Analogues with α-Methylene-γ-butyrolactone as Anticancer Agents: A Structure-Activity Relationship Study.. J Med Chem, 59 (10): (5121-5127). [PMID:27077228] [10.1021/acs.jmedchem.6b00400] |
| 103. Kumar V, Guru SK, Jain SK, Joshi P, Gandhi SG, Bharate SB, Bhushan S, Bharate SS, Vishwakarma RA.. (2016) A chromatography-free isolation of rohitukine from leaves of Dysoxylum binectariferum: Evaluation for in vitro cytotoxicity, Cdk inhibition and physicochemical properties.. Bioorg Med Chem Lett, 26 (15): (3457-3463). [PMID:27363938] [10.1016/j.bmcl.2016.06.046] |
| 104. Kim H, Lee C, Yang JS, Choi S, Park CH, Kang JS, Oh SJ, Yun J, Kim MH, Han G.. (2016) Structural modifications at the 6-position of thieno[2,3-d]pyrimidines and their effects on potency at FLT3 for treatment of acute myeloid leukemia.. Eur J Med Chem, 120 (74-85). [PMID:27187860] [10.1016/j.ejmech.2016.05.022] |
| 105. Chen Y, Zheng Y, Jiang Q, Qin F, Zhang Y, Fu L, He G.. (2017) Integrated bioinformatics, computational and experimental methods to discover novel Raf/extracellular-signal regulated kinase (ERK) dual inhibitors against breast cancer cells.. Eur J Med Chem, 127 (997-1011). [PMID:27839788] [10.1016/j.ejmech.2016.11.009] |
| 106. Shi Y, Park J, Lagisetti C, Zhou W, Sambucetti LC, Webb TR.. (2017) A triple exon-skipping luciferase reporter assay identifies a new CLK inhibitor pharmacophore.. Bioorg Med Chem Lett, 27 (3): (406-412). [PMID:28049589] [10.1016/j.bmcl.2016.12.056] |
| 107. Cai Y, Li W, Tu H, Chen N, Zhong Z, Yan P, Dong J.. (2017) Curcumolide reduces diabetic retinal vascular leukostasis and leakage partly via inhibition of the p38MAPK/NF-κ B signaling.. Bioorg Med Chem Lett, 27 (8): (1835-1839). [PMID:28274631] [10.1016/j.bmcl.2017.02.045] |
| 108. Hamed MM, Darwish SS, Herrmann J, Abadi AH, Engel M.. (2017) First Bispecific Inhibitors of the Epidermal Growth Factor Receptor Kinase and the NF-κB Activity As Novel Anticancer Agents.. J Med Chem, 60 (7): (2853-2868). [PMID:28291344] [10.1021/acs.jmedchem.6b01774] |
| 109. Wang S, Xu L, Lu YT, Liu YF, Han B, Liu T, Tang J, Li J, Wu J, Li JY, Yu LF, Yang F.. (2017) Discovery of benzofuran-3(2H)-one derivatives as novel DRAK2 inhibitors that protect islet β-cells from apoptosis.. Eur J Med Chem, 130 (195-208). [PMID:28249207] [10.1016/j.ejmech.2017.02.048] |
| 110. Williamson DS, Smith GP, Acheson-Dossang P, Bedford ST, Chell V, Chen IJ, Daechsel JCA, Daniels Z, David L, Dokurno P, Hentzer M, Herzig MC, Hubbard RE, Moore JD, Murray JB, Newland S, Ray SC, Shaw T, Surgenor AE, Terry L, Thirstrup K, Wang Y, Christensen KV.. (2017) Design of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors Using a Crystallographic Surrogate Derived from Checkpoint Kinase 1 (CHK1).. J Med Chem, 60 (21): (8945-8962). [PMID:29023112] [10.1021/acs.jmedchem.7b01186] |
| 111. Singh U, Chashoo G, Khan SU, Mahajan P, Nargotra A, Mahajan G, Singh A, Sharma A, Mintoo MJ, Guru SK, Aruri H, Thatikonda T, Sahu P, Chibber P, Kumar V, Mir SA, Bharate SS, Madishetti S, Nandi U, Singh G, Mondhe DM, Bhushan S, Malik F, Mignani S, Vishwakarma RA, Singh PP.. (2017) Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model.. J Med Chem, 60 (23): (9470-9489). [PMID:29144137] [10.1021/acs.jmedchem.7b00663] |
| 112. Smith GP, Badolo L, Chell V, Chen IJ, Christensen KV, David L, Daechsel JA, Hentzer M, Herzig MC, Mikkelsen GK, Watson SP, Williamson DS.. (2017) The design and SAR of a novel series of 2-aminopyridine based LRRK2 inhibitors.. Bioorg Med Chem Lett, 27 (18): (4500-4505). [PMID:28802631] [10.1016/j.bmcl.2017.07.072] |
| 113. Zhang H, Wu W, Feng C, Liu Z, Bai E, Wang X, Lei M, Cheng H, Feng H, Shi J, Wang J, Zhang Z, Jin T, Chen S, Hu S, Zhu Y.. (2017) Design, synthesis, SAR discussion, in vitro and in vivo evaluation of novel selective EGFR modulator to inhibit L858R/T790M double mutants.. Eur J Med Chem, 135 (12-23). [PMID:28426996] [10.1016/j.ejmech.2017.04.036] |
| 114. Fukuda T, Goto R, Kiho T, Ueda K, Muramatsu S, Hashimoto M, Aki A, Watanabe K, Tanaka N.. (2017) Discovery of DS79182026: A potent orally active hepcidin production inhibitor.. Bioorg Med Chem Lett, 27 (16): (3716-3722). [PMID:28705644] [10.1016/j.bmcl.2017.07.004] |
| 115. Patel S, Meilandt WJ, Erickson RI, Chen J, Deshmukh G, Estrada AA, Fuji RN, Gibbons P, Gustafson A, Harris SF, Imperio J, Liu W, Liu X, Liu Y, Lyssikatos JP, Ma C, Yin J, Lewcock JW, Siu M.. (2017) Selective Inhibitors of Dual Leucine Zipper Kinase (DLK, MAP3K12) with Activity in a Model of Alzheimer's Disease.. J Med Chem, 60 (19): (8083-8102). [PMID:28929759] [10.1021/acs.jmedchem.7b00843] |
| 116. Fukuda T, Goto R, Kiho T, Ueda K, Muramatsu S, Hashimoto M, Aki A, Watanabe K, Tanaka N.. (2017) Discovery of DS28120313 as a potent orally active hepcidin production inhibitor: Design and optimization of novel 4,6-disubstituted indazole derivatives.. Bioorg Med Chem Lett, 27 (23): (5252-5257). [PMID:29079471] [10.1016/j.bmcl.2017.10.031] |
| 117. Gege C, Cummings MD, Albers M, Kinzel O, Kleymann G, Schlüter T, Steeneck C, Nelen MI, Milligan C, Spurlino J, Xue X, Leonard K, Edwards JP, Fourie A, Goldberg SD, Hoffmann T.. (2018) Identification and biological evaluation of thiazole-based inverse agonists of RORγt.. Bioorg Med Chem Lett, 28 (9): (1446-1455). [PMID:29631962] [10.1016/j.bmcl.2018.03.093] |
| 118. Malainer C, Schachner D, Sangiovanni E, Atanasov AG, Schwaiger S, Stuppner H, Heiss EH, Dirsch VM.. (2017) Eurycomalactone Inhibits Expression of Endothelial Adhesion Molecules at a Post-Transcriptional Level.. J Nat Prod, 80 (12): (3186-3193). [PMID:29148754] [10.1021/acs.jnatprod.7b00503] |
| 119. Reiersølmoen AC, Han J, Sundby E, Hoff BH.. (2018) Identification of fused pyrimidines as interleukin 17 secretion inhibitors.. Eur J Med Chem, 155 (562-578). [PMID:29909341] [10.1016/j.ejmech.2018.06.019] |
| 120. Thakkar M, Bhuniya D, Kaduskar R, Mengawade T, Naik K, Salunkhe V, Bhalerao A, Kurhade S, Mavinahalli J, Jain V, Petla R, Avaragolla S, Ray S, Rouduri S, Dhanave A, De S, Pathade V, Tambe A, Raje AA, Madgula V, Joshi S, Nadeem A, Bala M, Umrani D, Hariharan N, Kulkarni B, Mookhtiar KA.. (2017) Discovery and evaluation of 1H-pyrrolo[2,3-b]pyridine based selective and reversible small molecule BTK inhibitors for the treatment of rheumatoid arthritis.. Bioorg Med Chem Lett, 27 (8): (1867-1873). [PMID:28279528] [10.1016/j.bmcl.2017.02.026] |
| 121. Monastyrskyi A, Nilchan N, Quereda V, Noguchi Y, Ruiz C, Grant W, Cameron M, Duckett D, Roush W.. (2018) Development of dual casein kinase 1δ/1ε (CK1δ/ε) inhibitors for treatment of breast cancer.. Bioorg Med Chem, 26 (3): (590-602). [PMID:29289448] [10.1016/j.bmc.2017.12.020] |
| 122. Assadieskandar A, Yu C, Maisonneuve P, Liu X, Chen YC, Prakash GKS, Kurinov I, Sicheri F, Zhang C.. (2018) Effects of rigidity on the selectivity of protein kinase inhibitors.. Eur J Med Chem, 146 (519-528). [PMID:29407977] [10.1016/j.ejmech.2018.01.053] |
| 123. Wang Q, Liu F, Qi S, Qi Z, Yan XE, Wang B, Wang A, Wang W, Chen C, Liu X, Jiang Z, Hu Z, Wang L, Wang W, Ren T, Zhang S, Yun CH, Liu Q, Liu J.. (2018) Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia.. Eur J Med Chem, 150 (366-384). [PMID:29544149] [10.1016/j.ejmech.2018.03.003] |
| 124. He LJ, Yang DL, Li SQ, Zhang YJ, Tang Y, Lei J, Frett B, Lin HK, Li HY, Chen ZZ, Xu ZG.. (2018) Facile construction of fused benzimidazole-isoquinolinones that induce cell-cycle arrest and apoptosis in colorectal cancer cells.. Bioorg Med Chem, 26 (14): (3899-3908). [PMID:29921474] [10.1016/j.bmc.2018.06.010] |
| 125. Pan Z, Chen Y, Liu J, Jiang Q, Yang S, Guo L, He G.. (2018) Design, synthesis, and biological evaluation of polo-like kinase 1/eukaryotic elongation factor 2 kinase (PLK1/EEF2K) dual inhibitors for regulating breast cancer cells apoptosis and autophagy.. Eur J Med Chem, 144 (517-528). [PMID:29288948] [10.1016/j.ejmech.2017.12.046] |
| 126. Liu H, Liang H, Meng H, Deng X, Zhang X, Lai L.. (2018) A novel allosteric inhibitor that prevents IKKβ activation.. Medchemcomm, 9 (2): (239-243). [PMID:30108917] [10.1039/C7MD00599G] |
| 127. Jiang JK, Huang X, Shamim K, Patel PR, Lee A, Wang AQ, Nguyen K, Tawa G, Cuny GD, Yu PB, Zheng W, Xu X, Sanderson P, Huang W.. (2018) Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors.. Bioorg Med Chem Lett, 28 (20): (3356-3362). [PMID:30227946] [10.1016/j.bmcl.2018.09.006] |
| 128. Wang B, Wu J, Wu Y, Chen C, Zou F, Wang A, Wu H, Hu Z, Jiang Z, Liu Q, Wang W, Zhang Y, Liu F, Zhao M, Hu J, Huang T, Ge J, Wang L, Ren T, Wang Y, Liu J, Liu Q.. (2018) Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor.. Eur J Med Chem, 158 (896-916). [PMID:30253346] [10.1016/j.ejmech.2018.09.025] |
| 129. Zhang Y, Lv H, Luo L, Xu Y, Pan Y, Wang Y, Lin H, Xiong J, Guo P, Zhang J, Li X, Ye F.. (2018) Design, synthesis and pharmacological evaluation of N4,N6-disubstituted pyrimidine-4,6-diamine derivatives as potent EGFR inhibitors in non-small cell lung cancer.. Eur J Med Chem, 157 (1300-1325). [PMID:30195240] [10.1016/j.ejmech.2018.08.031] |
| 130. Janganati V, Ponder J, Balasubramaniam M, Bhat-Nakshatri P, Bar EE, Nakshatri H, Jordan CT, Crooks PA.. (2018) MMB triazole analogs are potent NF-κB inhibitors and anti-cancer agents against both hematological and solid tumor cells.. Eur J Med Chem, 157 (562-581). [PMID:30121494] [10.1016/j.ejmech.2018.08.010] |
| 131. Dodo K, Kuboki E, Shimizu T, Imamura R, Magarisawa M, Takahashi M, Tokuhiro T, Yotsumoto S, Asano K, Nakao S, Terayama N, Suda T, Tanaka M, Sodeoka M.. (2019) Development of a Water-Soluble Indolylmaleimide Derivative IM-93 Showing Dual Inhibition of Ferroptosis and NETosis.. ACS Med Chem Lett, 10 (9): (1272-1278). [PMID:31531196] [10.1021/acsmedchemlett.9b00142] |
| 132. Zhang Q, Hu X, Wan G, Wang J, Li L, Wu X, Liu Z, Yu L.. (2019) Discovery of 3-(((9H-purin-6-yl)amino)methyl)-4,6-dimethylpyridin-2(1H)-one derivatives as novel tubulin polymerization inhibitors for treatment of cancer.. Eur J Med Chem, 184 (111728-111728). [PMID:31610375] [10.1016/j.ejmech.2019.111728] |
| 133. Rana S, Sonawane YA, Taylor MA, Kizhake S, Zahid M, Natarajan A.. (2018) Synthesis of aminopyrazole analogs and their evaluation as CDK inhibitors for cancer therapy.. Bioorg Med Chem Lett, 28 (23-24): (3736-3740). [PMID:30343954] [10.1016/j.bmcl.2018.10.020] |
| 134. Narayan S, Ramisetti S, Jaiswal AS, Law BK, Singh-Pillay A, Singh P, Amin S, Sharma AK.. (2019) ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.. Eur J Med Chem, 161 (456-467). [PMID:30384048] [10.1016/j.ejmech.2018.10.052] |
| 135. Osborne J, Birchall K, Tsagris DJ, Lewis SJ, Smiljanic-Hurley E, Taylor DL, Levy A, Alessi DR, McIver EG.. (2019) Discovery of potent and selective 5-azaindazole inhibitors of leucine-rich repeat kinase 2 (LRRK2) - Part 1.. Bioorg Med Chem Lett, 29 (4): (668-673). [PMID:30554956] [10.1016/j.bmcl.2018.11.058] |
| 136. Wang Y, Dou X, Jiang L, Jin H, Zhang L, Zhang L, Liu Z.. (2019) Discovery of novel glycogen synthase kinase-3α inhibitors: Structure-based virtual screening, preliminary SAR and biological evaluation for treatment of acute myeloid leukemia.. Eur J Med Chem, 171 (221-234). [PMID:30925338] [10.1016/j.ejmech.2019.03.039] |
| 137. Martínez-González S, Rodríguez-Arístegui S, Gómez de la Oliva CA, Hernández AI, González Cantalapiedra E, Varela C, García AB, Rabal O, Oyarzabal J, Bischoff JR, Klett J, Albarrán MI, Cebriá A, Ajenjo N, García-Serelde B, Gómez-Casero E, Cuadrado-Urbano M, Cebrián D, Blanco-Aparicio C, Pastor J.. (2019) Discovery of novel triazolo[4,3-b]pyridazin-3-yl-quinoline derivatives as PIM inhibitors.. Eur J Med Chem, 168 (87-109). [PMID:30802730] [10.1016/j.ejmech.2019.02.022] |
| 138. Yuan T, Qi B, Jiang Z, Dong W, Zhong L, Bai L, Tong R, Yu J, Shi J.. (2019) Dual FLT3 inhibitors: Against the drug resistance of acute myeloid leukemia in recent decade.. Eur J Med Chem, 178 (468-483). [PMID:31207462] [10.1016/j.ejmech.2019.06.002] |
| 139. Wang X, Yu C, Wang C, Ma Y, Wang T, Li Y, Huang Z, Zhou M, Sun P, Zheng J, Yang S, Fan Y, Xiang R.. (2019) Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer.. Eur J Med Chem, 181 (111535-111535). [PMID:31376566] [10.1016/j.ejmech.2019.07.038] |
| 140. Zhao L, Li Y, Wang Y, Qiao Z, Miao Z, Yang J, Huang L, Tian C, Li L, Chen D, Yang S.. (2019) Discovery of 4H-Chromen-4-one Derivatives as a New Class of Selective Rho Kinase (ROCK) Inhibitors, which Showed Potent Activity in ex Vivo Diabetic Retinopathy Models.. J Med Chem, 62 (23): (10691-10710). [PMID:31693351] [10.1021/acs.jmedchem.9b01143] |
| 141. Jang J, Son JB, To C, Bahcall M, Kim SY, Kang SY, Mushajiang M, Lee Y, Jänne PA, Choi HG, Gray NS.. (2017) Discovery of a potent dual ALK and EGFR T790M inhibitor.. Eur J Med Chem, 136 (497-510). [PMID:28528303] [10.1016/j.ejmech.2017.04.079] |
| 142. Oukoloff K, Coquelle N, Bartolini M, Naldi M, Le Guevel R, Bach S, Josselin B, Ruchaud S, Catto M, Pisani L, Denora N, Iacobazzi RM, Silman I, Sussman JL, Buron F, Colletier JP, Jean L, Routier S, Renard PY.. (2019) Design, biological evaluation and X-ray crystallography of nanomolar multifunctional ligands targeting simultaneously acetylcholinesterase and glycogen synthase kinase-3.. Eur J Med Chem, 168 (58-77). [PMID:30798053] [10.1016/j.ejmech.2018.12.063] |
| 143. Andrews LD, Kane TR, Dozzo P, Haglund CM, Hilderbrandt DJ, Linsell MS, Machajewski T, McEnroe G, Serio AW, Wlasichuk KB, Neau DB, Pakhomova S, Waldrop GL, Sharp M, Pogliano J, Cirz RT, Cohen F.. (2019) Optimization and Mechanistic Characterization of Pyridopyrimidine Inhibitors of Bacterial Biotin Carboxylase.. J Med Chem, 62 (16): (7489-7505). [PMID:31306011] [10.1021/acs.jmedchem.9b00625] |
| 144. Kang SJ, Lee JW, Chung SH, Jang SY, Choi J, Suh KH, Kim YH, Ham YJ, Min KH.. (2019) Synthesis and anti-tumor activity of imidazopyrazines as TAK1 inhibitors.. Eur J Med Chem, 163 (660-670). [PMID:30576901] [10.1016/j.ejmech.2018.12.025] |
| 145. Moslin R, Zhang Y, Wrobleski ST, Lin S, Mertzman M, Spergel S, Tokarski JS, Strnad J, Gillooly K, McIntyre KW, Zupa-Fernandez A, Cheng L, Sun H, Chaudhry C, Huang C, D'Arienzo C, Heimrich E, Yang X, Muckelbauer JK, Chang C, Tredup J, Mulligan D, Xie D, Aranibar N, Chiney M, Burke JR, Lombardo L, Carter PH, Weinstein DS.. (2019) Identification of N-Methyl Nicotinamide and N-Methyl Pyridazine-3-Carboxamide Pseudokinase Domain Ligands as Highly Selective Allosteric Inhibitors of Tyrosine Kinase 2 (TYK2).. J Med Chem, 62 (20): (8953-8972). [PMID:31314518] [10.1021/acs.jmedchem.9b00443] |
| 146. Ikegashira K, Ikenogami T, Yamasaki T, Oka T, Hase Y, Miyagawa N, Inagaki K, Kawahara I, Koga Y, Hashimoto H.. (2019) Optimization of an azetidine series as inhibitors of colony stimulating factor-1 receptor (CSF-1R) Type II to lead to the clinical candidate JTE-952.. Bioorg Med Chem Lett, 29 (7): (873-877). [PMID:30755337] [10.1016/j.bmcl.2019.02.006] |
| 147. Zak M,Hanan EJ,Lupardus P,Brown DG,Robinson C,Siu M,Lyssikatos JP,Romero FA,Zhao G,Kellar T,Mendonca R,Ray NC,Goodacre SC,Crackett PH,McLean N,Hurley CA,Yuen PW,Cheng YX,Liu X,Liimatta M,Kohli PB,Nonomiya J,Salmon G,Buckley G,Lloyd J,Gibbons P,Ghilardi N,Kenny JR,Johnson A. (2019) Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling.. Bioorg Med Chem Lett, 29 (12.0): (1522-1531). [PMID:30981576] [10.1016/j.bmcl.2019.04.008] |
| 148. Hamilton GL,Chen H,Deshmukh G,Eigenbrot C,Fong R,Johnson A,Kohli PB,Lupardus PJ,Liederer BM,Ramaswamy S,Wang H,Wang J,Xu Z,Zhu Y,Vucic D,Patel S. (2019) Potent and selective inhibitors of receptor-interacting protein kinase 1 that lack an aromatic back pocket group.. Bioorg Med Chem Lett, 29 (12.0): (1497-1501). [PMID:31000154] [10.1016/j.bmcl.2019.04.014] |
| 149. Mahajan D,Sen S,Kuila B,Sharma A,Arora R,Sagar M,Mahapatra AR,Gawade LB,Dugar S. (2020) Discovery and Development of SPR519 as a Potent, Selective, and Orally Bioavailable Inhibitor of PI3Kα and mTOR Kinases for the Treatment of Solid Tumors.. J Med Chem, 63 (19): (11121-11130). [PMID:32897703] [10.1021/acs.jmedchem.0c01061] |
| 150. Ding X,Stasi LP,Ho MH,Zhao B,Wang H,Long K,Xu Q,Sang Y,Sun C,Hu H,Yu H,Wan Z,Wang L,Edge C,Liu Q,Li Y,Dong K,Guan X,Tattersall FD,Reith AD,Ren F. (2018) Discovery of 4-ethoxy-7H-pyrrolo[2,3-d]pyrimidin-2-amines as potent, selective and orally bioavailable LRRK2 inhibitors.. Bioorg Med Chem Lett, 28 (9.0): (1615-1620). [PMID:29588215] [10.1016/j.bmcl.2018.03.045] |
| 151. Yang J,Chen K,Zhang G,Yang QY,Li YS,Huang SZ,Wang YL,Yang W,Jiang XJ,Yan HX,Zhu JQ,Xiang R,Luo YF,Li WM,Wei YQ,Li LL,Yang SY. (2018) Structural optimization and structure-activity relationship studies of N-phenyl-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-4-amine derivatives as a new class of inhibitors of RET and its drug resistance mutants.. Eur J Med Chem, 143 (1148-1164). [PMID:29133048] [10.1016/j.ejmech.2017.09.018] |
| 152. Mercurio, F F and 10 more authors.. (1997) IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation.. Science (New York, N.Y.), (31): [PMID:9346484] |
| 153. Woronicz, J D JD, Gao, X X, Cao, Z Z, Rothe, M M and Goeddel, D V DV.. (1997) IkappaB kinase-beta: NF-kappaB activation and complex formation with IkappaB kinase-alpha and NIK.. Science (New York, N.Y.), (31): [PMID:9346485] |
| 154. Cohen, L L, Henzel, W J WJ and Baeuerle, P A PA.. (1998) IKAP is a scaffold protein of the IkappaB kinase complex.. Nature, (17): [PMID:9751059] |
| 155. Shindo, M M and 5 more authors.. (1998) Assignment of IkappaB kinase beta (IKBKB) to human chromosome band 8p12-->p11 by in situ hybridization.. Cytogenetics and cell genetics, [PMID:9763654] |
| 156. Hu, M C MC and Wang, Y Y.. (1998) IkappaB kinase-alpha and -beta genes are coexpressed in adult and embryonic tissues but localized to different human chromosomes.. Gene, (5): [PMID:9813230] |
| 157. Nemoto, S S, DiDonato, J A JA and Lin, A A.. (1998) Coordinate regulation of IkappaB kinases by mitogen-activated protein kinase kinase kinase 1 and NF-kappaB-inducing kinase.. Molecular and cellular biology, [PMID:9819420] |
| 158. Lallena, M J MJ, Diaz-Meco, M T MT, Bren, G G, Payá, C V CV and Moscat, J J.. (1999) Activation of IkappaB kinase beta by protein kinase C isoforms.. Molecular and cellular biology, [PMID:10022904] |
| 159. Delhase, M M, Hayakawa, M M, Chen, Y Y and Karin, M M.. (1999) Positive and negative regulation of IkappaB kinase activity through IKKbeta subunit phosphorylation.. Science (New York, N.Y.), (9): [PMID:10195894] |
| 160. Sanz, L L, Sanchez, P P, Lallena, M J MJ, Diaz-Meco, M T MT and Moscat, J J.. (1999) The interaction of p62 with RIP links the atypical PKCs to NF-kappaB activation.. The EMBO journal, (1): [PMID:10356400] |
| 161. Jobin, C C and Sartor, R B RB.. (2000) The I kappa B/NF-kappa B system: a key determinant of mucosalinflammation and protection.. American journal of physiology. Cell physiology, [PMID:10712233] |
| 162. Yamamoto, Y Y, Yin, M J MJ and Gaynor, R B RB.. (2000) IkappaB kinase alpha (IKKalpha) regulation of IKKbeta kinase activity.. Molecular and cellular biology, [PMID:10779355] |
| 163. Tojima, Y Y and 11 more authors.. (2000) NAK is an IkappaB kinase-activating kinase.. Nature, (13): [PMID:10783893] |
| 164. Bonnet, M C MC, Weil, R R, Dam, E E, Hovanessian, A G AG and Meurs, E F EF.. (2000) PKR stimulates NF-kappaB irrespective of its kinase function by interacting with the IkappaB kinase complex.. Molecular and cellular biology, [PMID:10848580] |
| 165. Weber, C K CK, Liptay, S S, Wirth, T T, Adler, G G and Schmid, R M RM.. (2000) Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta.. Gastroenterology, [PMID:11054378] |
| 166. Salmerón, A A and 6 more authors.. (2001) Direct phosphorylation of NF-kappaB1 p105 by the IkappaB kinase complex on serine 927 is essential for signal-induced p105 proteolysis.. The Journal of biological chemistry, (22): [PMID:11297557] |
| 167. Chen, X X, Ji, Z L ZL and Chen, Y Z YZ.. (2002) TTD: Therapeutic Target Database.. Nucleic acids research, (1): [PMID:11752352] |
| 168. Wu, Ray-Chang RC and 7 more authors.. (2002) Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) Coactivator activity by I kappa B kinase.. Molecular and cellular biology, [PMID:11971985] |
| 169. Chariot, Alain A and 5 more authors.. (2002) Association of the adaptor TANK with the I kappa B kinase (IKK) regulator NEMO connects IKK complexes with IKK epsilon and TBK1 kinases.. The Journal of biological chemistry, (4): [PMID:12133833] |
| 170. Tegethoff, Sebastian S, Behlke, Joachim J and Scheidereit, Claus C.. (2003) Tetrameric oligomerization of IkappaB kinase gamma (IKKgamma) is obligatory for IKK complex activity and NF-kappaB activation.. Molecular and cellular biology, [PMID:12612076] |
| 171. Allgayer, H H.. (2003) Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease.. Alimentary pharmacology & therapeutics, [PMID:12950415] |
| 172. Han, Ke-Jun KJ and 5 more authors.. (2004) Mechanisms of the TRIF-induced interferon-stimulated response element and NF-kappaB activation and apoptosis pathways.. The Journal of biological chemistry, (9): [PMID:14739303] |
| 173. Röhl, Mathias M and 9 more authors.. (2004) Conditional disruption of IkappaB kinase 2 fails to prevent obesity-induced insulin resistance.. The Journal of clinical investigation, [PMID:14755344] |
| 174. Hu, Mickey C-T MC and 11 more authors.. (2004) IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a.. Cell, (16): [PMID:15084260] |
| 175. Bruey, Jean Marie JM and 5 more authors.. (2004) PAN1/NALP2/PYPAF2, an inducible inflammatory mediator that regulates NF-kappaB and caspase-1 activation in macrophages.. The Journal of biological chemistry, (10): [PMID:15456791] |
| 176. Hu, Wen-Hui WH and 10 more authors.. (2005) NIBP, a novel NIK and IKK(beta)-binding protein that enhances NF-(kappa)B activation.. The Journal of biological chemistry, (12): [PMID:15951441] |
| 177. Meylan, Etienne E and 6 more authors.. (2005) Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus.. Nature, (20): [PMID:16177806] |
| 178. Tanaka, Hiroshi H, Fujita, Naoya N and Tsuruo, Takashi T.. (2005) 3-Phosphoinositide-dependent protein kinase-1-mediated IkappaB kinase beta (IkkB) phosphorylation activates NF-kappaB signaling.. The Journal of biological chemistry, (9): [PMID:16207722] |
| 179. Ouyang, Weiming W and 6 more authors.. (2005) Cyclin D1 induction through IkappaB kinase beta/nuclear factor-kappaB pathway is responsible for arsenite-induced increased cell cycle G1-S phase transition in human keratinocytes.. Cancer research, (15): [PMID:16230390] |
| 180. Carter, Robert S RS, Pennington, Kevin N KN, Arrate, Pia P, Oltz, Eugene M EM and Ballard, Dean W DW.. (2005) Site-specific monoubiquitination of IkappaB kinase IKKbeta regulates its phosphorylation and persistent activation.. The Journal of biological chemistry, (30): [PMID:16267042] |
| 181. Nusbaum, Chad C and 75 more authors.. (2006) DNA sequence and analysis of human chromosome 8.. Nature, (19): [PMID:16421571] |
| 182. Wu, Zhao-Hui ZH, Shi, Yuling Y, Tibbetts, Randal S RS and Miyamoto, Shigeki S.. (2006) Molecular linkage between the kinase ATM and NF-kappaB signaling in response to genotoxic stimuli.. Science (New York, N.Y.), (24): [PMID:16497931] |
| 183. Mukherjee, Sohini S and 6 more authors.. (2006) Yersinia YopJ acetylates and inhibits kinase activation by blocking phosphorylation.. Science (New York, N.Y.), (26): [PMID:16728640] |
| 184. Sjöblom, Tobias T and 28 more authors.. (2006) The consensus coding sequences of human breast and colorectal cancers.. Science (New York, N.Y.), (13): [PMID:16959974] |
| 185. Youn, Hyung S HS, Lee, Joo Y JY, Saitoh, Shin I SI, Miyake, Kensuke K and Hwang, Daniel H DH.. (2006) Auranofin, as an anti-rheumatic gold compound, suppresses LPS-induced homodimerization of TLR4.. Biochemical and biophysical research communications, (1): [PMID:17034761] |
| 186. Cummins, Eoin P EP and 10 more authors.. (2006) Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity.. Proceedings of the National Academy of Sciences of the United States of America, (28): [PMID:17114296] |
| 187. Lobry, Camille C, Lopez, Tatiana T, Israël, Alain A and Weil, Robert R.. (2007) Negative feedback loop in T cell activation through IkappaB kinase-induced phosphorylation and degradation of Bcl10.. Proceedings of the National Academy of Sciences of the United States of America, (16): [PMID:17213322] |
| 188. Ohnuma, Kei K and 10 more authors.. (2007) Caveolin-1 triggers T-cell activation via CD26 in association with CARMA1.. The Journal of biological chemistry, (30): [PMID:17287217] |
| 189. Ouyang, Weiming W, Zhang, Dongyun D, Ma, Qian Q, Li, Jingxia J and Huang, Chuanshu C.. (2007) Cyclooxygenase-2 induction by arsenite through the IKKbeta/NFkappaB pathway exerts an antiapoptotic effect in mouse epidermal Cl41 cells.. Environmental health perspectives, [PMID:17450217] |
| 190. Park, Min-Young MY and 6 more authors.. (2007) FAF1 suppresses IkappaB kinase (IKK) activation by disrupting the IKK complex assembly.. The Journal of biological chemistry, (21): [PMID:17684021] |
| 191. Solt, Laura A LA and May, Michael J MJ.. (2008) The IkappaB kinase complex: master regulator of NF-kappaB signaling.. Immunologic research, [PMID:18626576] |
| 192. Dephoure, Noah N and 6 more authors.. (2008) A quantitative atlas of mitotic phosphorylation.. Proceedings of the National Academy of Sciences of the United States of America, (5): [PMID:18669648] |
| 193. Daub, Henrik H and 9 more authors.. (2008) Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.. Molecular cell, (8): [PMID:18691976] |
| 194. Sun, Wenjing W and 12 more authors.. (2009) PPM1A and PPM1B act as IKKbeta phosphatases to terminate TNFalpha-induced IKKbeta-NF-kappaB activation.. Cellular signalling, [PMID:18930133] |
| 195. Wada, Keiji K, Niida, Motoko M, Tanaka, Makoto M and Kamitani, Tetsu T.. (2009) Ro52-mediated monoubiquitination of IKK{beta} down-regulates NF-{kappa}B signalling.. Journal of biochemistry, [PMID:19675099] |
| 196. Mayya, Viveka V and 7 more authors.. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.. Science signaling, (18): [PMID:19690332] |
| 197. Kuo, Hsu-Ping HP and 5 more authors.. (2009) Phosphorylation of ARD1 by IKKbeta contributes to its destabilization and degradation.. Biochemical and biophysical research communications, (6): [PMID:19716809] |
| 198. Yoboua, Fabrice F, Martel, Alexis A, Duval, Annick A, Mukawera, Espérance E and Grandvaux, Nathalie N.. (2010) Respiratory syncytial virus-mediated NF-kappa B p65 phosphorylation at serine 536 is dependent on RIG-I, TRAF6, and IKK beta.. Journal of virology, [PMID:20410276] |
| 199. Tsuchiya, Yoshihiro Y and 5 more authors.. (2010) Nuclear IKKbeta is an adaptor protein for IkappaBalpha ubiquitination and degradation in UV-induced NF-kappaB activation.. Molecular cell, (27): [PMID:20797629] |
| 200. Gamble, Carly C and 5 more authors.. (2012) Inhibitory kappa B Kinases as targets for pharmacological regulation.. British journal of pharmacology, [PMID:21797846] |
| 201. del Vescovo, Cosmo Damiano CD, Cotecchia, Susanna S and Diviani, Dario D.. (2013) A-kinase-anchoring protein-Lbc anchors IκB kinase β to support interleukin-6-mediated cardiomyocyte hypertrophy.. Molecular and cellular biology, [PMID:23090968] |
| 202. Wang, Wei W and 8 more authors.. (2012) The zinc finger protein ZNF268 is overexpressed in human cervical cancer and contributes to tumorigenesis via enhancing NF-κB signaling.. The Journal of biological chemistry, (14): [PMID:23091055] |
| 203. Zhou, Houjiang H and 6 more authors.. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome.. Journal of proteome research, (4): [PMID:23186163] |
| 204. Zhou, Alicia Y AY and 6 more authors.. (2013) IKKε-mediated tumorigenesis requires K63-linked polyubiquitination by a cIAP1/cIAP2/TRAF2 E3 ubiquitin ligase complex.. Cell reports, (28): [PMID:23453969] |
| 205. Dauphinee, Shauna M SM and 8 more authors.. (2013) SASH1 is a scaffold molecule in endothelial TLR4 signaling.. Journal of immunology (Baltimore, Md. : 1950), (15): [PMID:23776175] |
| 206. Pannicke, Ulrich U and 19 more authors.. (2013) Deficiency of innate and acquired immunity caused by an IKBKB mutation.. The New England journal of medicine, (26): [PMID:24369075] |
| 207. Alfonso, L; Ai, G; Spitale, R C and Bhat, G J.. (2014) Molecular targets of aspirin and cancer prevention.. British journal of cancer, (8): [PMID:24874482] |
| 208. Lopez-Pelaez, Marta M and 5 more authors.. (2014) Protein kinase IKKβ-catalyzed phosphorylation of IRF5 at Ser462 induces its dimerization and nuclear translocation in myeloid cells.. Proceedings of the National Academy of Sciences of the United States of America, (9): [PMID:25326418] |
| 209. Romano, Simona S and 10 more authors.. (2015) FKBP51 employs both scaffold and isomerase functions to promote NF-κB activation in melanoma.. Nucleic acids research, (18): [PMID:26101251] |
| 210. You, Dong-Joo DJ and 7 more authors.. (2015) Dimer of arfaptin 2 regulates NF-κB signaling by interacting with IKKβ/NEMO and inhibiting IKKβ kinase activity.. Cellular signalling, [PMID:26296658] |
| 211. Zheng, Caishang C and 7 more authors.. (2015) IFIT5 positively regulates NF-κB signaling through synergizing the recruitment of IκB kinase (IKK) to TGF-β-activated kinase 1 (TAK1).. Cellular signalling, [PMID:26334375] |
| 212. Wu, Chenglei C and 5 more authors.. (2016) LRRC14 attenuates Toll-like receptor-mediated NF-κB signaling through disruption of IKK complex.. Experimental cell research, (10): [PMID:27426725] |
| 213. Tang, Qingyu Q, Chakraborty, Sayan S and Xu, Guozhou G.. (2018) Mechanism of vaccinia viral protein B14-mediated inhibition of IκB kinase β activation.. The Journal of biological chemistry, (29): [PMID:29748387] |
| 214. Cardinez, Chelisa C and 23 more authors.. (2018) Gain-of-function IKBKB mutation causes human combined immune deficiency.. The Journal of experimental medicine, (5): [PMID:30337470] |
| 215. DeDiego, Marta L; Martinez-Sobrido, Luis and Topham, David J.. (2019) Novel Functions of IFI44L as a Feedback Regulator of Host Antiviral Responses.. Journal of virology, (1): [PMID:31434731] |
| 216. Gaisina IN, Gallier F, Ougolkov AV, Kim KH, Kurome T, Guo S, Holzle D, Luchini DN, Blond SY, Billadeau DD et al.. (2009) From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells.. J Med Chem, 52 (7): (1853-63). [PMID:19338355] [10.1021/op500134e] |
| 217. Thomas R Burkard,Melanie Planyavsky,Ines Kaupe,Florian P Breitwieser,Tilmann Bürckstümmer,Keiryn L Bennett,Giulio Superti-Furga,Jacques Colinge. (2011-01-29) Initial characterization of the human central proteome.. BMC systems biology, 5 (17-17). [PMID:21269460] |
| 218. May-Dracka TL,Arduini R,Bertolotti-Ciarlet A,Bhisetti G,Brickelmaier M,Cahir-McFarland E,Enyedy I,Fontenot JD,Hesson T,Little K,Lyssikatos J,Marcotte D,McKee T,Murugan P,Patterson T,Peng H,Rushe M,Silvian L,Spilker K,Wu P,Xin Z,Burkly LC. (2018) Investigating small molecules to inhibit germinal center kinase-like kinase (GLK/MAP4K3) upstream of PKCθ phosphorylation: Potential therapy to modulate T cell dependent immunity.. Bioorg Med Chem Lett, 28 (10): (1964-1971). [PMID:29636220] [10.1016/j.bmcl.2018.03.032] |
ZJ23F0700723